Laigle-Donadey Florence
Service de neurologie Mazarin, Hôpital Pitié-Salpêtrière, Paris, France.
Geriatr Psychol Neuropsychiatr Vieil. 2019 Jun 1;17(2):173-178. doi: 10.1684/pnv.2019.0799.
Incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors in gliomas. However, the previous nihilistic approach is progressively changing towards more active strategies. Particularly, prospective randomized studies have recently established the benefit of radiotherapy associated with concomitant and adjuvant chemotherapy by temozolomide in older patients with good functional status suffering from malignant gliomas. Chemotherapy alone may even be useful in this population, especially in patients with poor functional status. Symptomatic treatments such as corticosteroids and antiepileptic drugs may be less tolerated in this population compared to younger patients and should be used only if needed. Initial performance status, quality of life and concomitant pathologies are obviously important factors to consider before treatment onset. The willingness of the patient and his caregivers will also be the key of the therapeutic decision. In the future, it will be necessary to develop specific schedules of treatment in this population. For this reason, prospective randomized clinical trials are needed to improve the pattern of care of malignant glioma in the elderly.
恶性胶质瘤在老年人群中的发病率正在上升。不幸的是,年龄增长是胶质瘤最重要的负面预后因素之一。然而,以往的消极治疗方法正逐渐转向更积极的策略。特别是,前瞻性随机研究最近证实,对于功能状态良好的老年恶性胶质瘤患者,放疗联合替莫唑胺同步和辅助化疗是有益的。单纯化疗在这一人群中甚至可能有用,尤其是在功能状态较差的患者中。与年轻患者相比,这一人群对皮质类固醇和抗癫痫药物等对症治疗的耐受性可能较差,应仅在必要时使用。治疗开始前,初始功能状态、生活质量和伴随疾病显然是需要考虑的重要因素。患者及其护理人员的意愿也将是治疗决策的关键。未来,有必要为这一人群制定特定的治疗方案。因此,需要进行前瞻性随机临床试验,以改善老年恶性胶质瘤的治疗模式。